Introduction
Evonik has launched VECOLLAN®, a recombinant, non-animal-derived collagen-like protein, now available in a clinical-grade suitable for trials. This development supports medical devices aimed at improving patient safety and performance.
Applications and Advancements
VECOLLAN® is an innovation in biosynthetic processing, showing promise in fields like orthopedics, medical aesthetics, and sports medicine. It offers a reliable biomaterial that meets clinical use requirements.
Production and Sustainability
The protein is produced through a sustainable fermentation-based process, ensuring high purity and consistency. This addresses concerns related to animal-derived collagens, such as variability and potential allergic reactions.
Future Plans
Evonik aims to offer validated material to partners by 2026, enhancing VECOLLAN®'s potential applications in the medical device industry and providing a rapid commercialization pathway.
